drugset / Trial / NCT03868943
Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma
Phase 2
Terminated
2 enrolled
Wake Forest University Health Sciences
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelSupportive care
Summary
This phase II trial studies the side effects of solriamfetol in improving sleep in patients with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug. Giving solriamfetol may improve sleep, memory, fatigue, mood, or quality of life in patients with brain tumors (gliomas).
Timeline
- Start
- 2021-01-27
- Primary completion
- 2021-11-22
- Completion
- 2021-11-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Solriamfetol | Small molecule | 300 mg | Oral |